Skip to content
Biotech For FIRE
  • Biotech
  • Holorogy
  • Investing
  • Book Review
  • News
  • About Me
  • Subscribe
  • Contact

Talking about Biotech

This is for successful biotech investments

  • Home
  • Talking about Biotech
  • Page 6

Why you may wanna own those European biotech powerhouses (Part 1)

Posted by By biotechwarrior November 3, 2020Posted inTalking about BiotechNo Comments
We often think (correctly) that US biotechs lead the world in terms of developing the most innovative therapeutics, but Europe can't be ignored in terms of delivering innovation in biotech…
Read More

Why I like to invest in a category leader in allogeneic CART – Allogene (feat. management team, TPG, Pfizer, and Gilead)

Posted by By biotechwarrior November 2, 2020Posted inTalking about BiotechNo Comments
Improvement in genomic analysis is fueling increased understanding of disease pathology, and simultaneous improvement in gene editing technologies are having massive synergies in development of new breakthrough therapeutics - with…
Read More
Fundamentals solve problems of heavy stock prices – cases to help you HODL onto your darling biotech stocks

Fundamentals solve problems of heavy stock prices – cases to help you HODL onto your darling biotech stocks

Posted by By biotechwarrior November 1, 2020Posted inTalking about BiotechNo Comments
October 2020 is finally over! It has been a difficult month - every day, Dow Jones or S&P500 dropped 2-3%. After leaving my fund, I am focused on managing my…
Read More
Catalyst set-up drives short-term stock path – why you may not want to buy that dip in Galapagos (GLPG)

Catalyst set-up drives short-term stock path – why you may not want to buy that dip in Galapagos (GLPG)

Posted by By biotechwarrior November 1, 2020Posted inTalking about BiotechNo Comments
On August 18th 2020, Galapagos and Gilead put out some crazy press release that caught everyone (at least in biotech) by surprise. FDA notified Gilead that the FDA would not…
Read More
Story of Alexion – High barrier to entry drugs provide predictable and compounding growth

Story of Alexion – High barrier to entry drugs provide predictable and compounding growth

Posted by By biotechwarrior November 1, 2020Posted inTalking about BiotechNo Comments
Unlike consumer or industrials sectors, biotechnology is very different in that while scale of economies or network effects often serve as the barriers to entry for consumer or industrials companies,…
Read More
XBI – the most efficient way to invest in innovative biotech companies

XBI – the most efficient way to invest in innovative biotech companies

Posted by By biotechwarrior November 1, 2020Posted inTalking about BiotechNo Comments
Single stock investing in biotech is both risky and difficult - full of surprises at 6am (when companies start putting out press releases) or 4pm (when markets close). This is…
Read More

Posts pagination

Previous page 1 … 4 5 6
Recent posts
  • Pharma update: Bullish for 4Q24
  • Immunology market update (positive: $ABBV $UCB / negative: $JNJ, $NVS, $LLY, $BMY, $AMGN)
  • REGN’s CRL and its impact on wet AMD market: 2H23 Biotech/Pharma outlook
  • 2H23 Pharma/Biotech Outlook (Part. 1)
  • $RPRX: Curious case of insider activities at Royalty Pharma (CEO buying, but everyone else is selling)

Loading
Follow Us
  • X
About Me
Logo
Former Biotech hedge fund analyst turned internet writer. Biotech can be fun and help with our FIRE plan. Still got a long way to go and wanted to share my journey. I am a Baker Brother wannabe. You can reach me at biotechwarrior@biotechforfire.tech
Subscribe for the latest posts

Loading
Useful Links
  • Endpoints News
  • FiercePharma
  • FierceBiotech
Copyright 2026 — Biotech For FIRE. All rights reserved. Sinatra WordPress Theme
Scroll to Top